Rationale: Eslicarbazepine acetate (ESL) is a once-daily oral antiepileptic drug for the treatment of partial-onset seizures. Adverse events such as dizziness and somnolence reported in clinical studies suggest that ESL has detectable central nervous system (CNS) effects in addition to its antiepileptic effects. This Phase I study evaluated the abuse liability of ESL compared with that of alprazolam (ALP) and placebo (PBO) in recreational CNS depressant users. Methods: In this single-dose, randomized, double-blind, PBO-and active-controlled crossover study, healthy recreational CNS depressant users who could discern between ALP 2 mg and PBO received single oral doses of each of the following treatments with a washout interval of ≥7 days between each treatment: ESL (800 mg, 1600 mg, 2000 mg, and 2400 mg); ALP (1.5 mg and 3.0 mg); and PBO. Subjective measures, including visual analog scales (VASs) e.g., Drug-Liking (primary endpoint), and Addiction Research Center Inventory (ARCI) Morphine-Benzedrine Group (MBG), Pentobarbital Chlorpromazine Alcohol Group (PCAG), and Lysergic Acid Diethylamide Group scales were evaluated at multiple time points up to 24 h postdose. Cognitive effects were evaluated using the Choice Reaction Time (CRT), Divided Attention (DAT) and Hopkins Verbal Learning Task-Revised tests. Principal results: Peak scores for Drug-Liking VAS (maximum effect [E max ]) were significantly higher for both ALP doses than for PBO (p b 0.0001), thereby confirming study validity. Drug-Liking VAS E max was significantly lower for all ESL doses than both ALP doses (p b 0.0001). Drug-Liking VAS E max for ESL 800 mg was similar to that for PBO (least squares [LS] mean difference: 3.6; p = 0.19). At the three higher ESL doses (1600 mg and the supratherapeutic doses of 2000 mg and 2400 mg), Drug-Liking VAS E max was significantly higher than for PBO, although the differences were minimal (LS mean difference: 9.3-13.3 out of 100). For most secondary subjective endpoints (i.e., Good Effects VAS and High VAS, ARCI-MBG, Take Drug Again VAS, Overall Drug-Liking VAS, and ARCI-PCAG; p b 0.05), the effect of ESL (all doses) was significantly less than that of ALP (both doses). On most secondary measures, the dose-response relationship was relatively flat or showed saturation at higher ESL doses. Although significant differences were observed for ESL compared with those for PBO for some specific CRT and DAT endpoints (i.e., reaction time, manual tracking, hit latency), ALP demonstrated significant and dose-dependent impairment on the majority of cognitive endpoints when compared with PBO and ESL. Mean plasma concentrations of the active metabolite of ESL, eslicarbazepine, increased with increasing ESL dose. Pharmacokinetic parameters estimated for eslicarbazepine were generally comparable with results from previous studies in healthy volunteers. Conclusion: This study demonstrated that single doses of ESL may have less abuse liability than ALP in recreational sedative users. Although ESL had detectable subjective effects and showed some drug-'liking' at higher doses, the magnitude of these effects was small.
Introduction
Eslicarbazepine acetate (ESL) is a once-daily oral antiepileptic drug (AED), approved by the US Food and Drug Administration (FDA) for the treatment of partial-onset seizures (POS) as monotherapy or adjunctive therapy. Eslicarbazepine acetate is approved by the European Medicines Agency as adjunctive therapy of POS in adults and by Health Canada as adjunctive therapy of POS in patients with epilepsy whose seizures are not satisfactorily controlled with conventional therapy. Following oral administration, ESL is extensively converted to the active metabolite eslicarbazepine [1] , which is thought to act primarily by stabilizing the inactivated state of voltage-gated sodium channels and delaying its return to the resting state, thus leading to inhibition of repetitive neuronal firing [2] . The efficacy and safety of ESL as adjunctive therapy and as monotherapy in patients with POS have been demonstrated in Phase III studies [3] [4] [5] [6] [7] [8] [9] .
Adverse events (AEs) recorded in Phase III clinical studies of ESL included dizziness, headache, and somnolence [3, 5, [7] [8] [9] suggesting that ESL has detectable central nervous system (CNS) effects in addition to its effects as an AED. As such, a premarket assessment of abuse potential, which included a review of the chemistry, pharmacology, animal behavior, pharmacokinetics, and safety data for ESL, was required as per the FDA Guidance on the Assessment of Abuse Potential of Drugs [10] . Results from preclinical abuse liability studies, including a drug discrimination study in rhesus monkeys, demonstrated that ESL does not induce benzodiazepine-like subjective effects. However, based on its CNS AE profile in Phase I to Phase III studies, a human abuse liability study was conducted. The purpose of the study was to evaluate possible abuse-related effects of therapeutic and supratherapeutic single oral doses of ESL compared with those of placebo (PBO) and alprazolam (ALP), a scheduled drug with sedative effects (i.e., positive control) [11, 12] . Nondependent recreational users of CNS depressants were selected for participation in the study because they represent the population at greatest risk of abuse of a compound with potential sedative effects, and they could provide meaningful ratings of the drug experiences with a lower risk of false negative results [10, [13] [14] [15] .
Material and methods
This Phase I, single-dose, randomized, double-blind, double-dummy, PBO-and active-controlled crossover study (093-153) was conducted at a single site in Toronto, Ontario, Canada, in accordance with the Declaration of Helsinki and the International Conference on Harmonization/Good Clinical Practice Guidelines. The study protocol was reviewed and approved by an Institutional Review Board (Ontario Institutional Review Board, Aurora, Ontario, Canada), and all subjects provided written, informed consent prior to study initiation.
Study population
Subjects were healthy male and female recreational CNS depressant users aged between 18 and 55 years, with a body mass index (BMI) of 18 to 33 kg/m 2 and a minimum weight of 50 kg at screening. They were required to have had ≥ 10 nontherapeutic lifetime experiences with CNS depressants (specifically, sedative or hypnotic use) including at least one nontherapeutic use within the 12 months prior to screening; the use of subjects with a history of relevant recreational drug use is consistent with current FDA guidelines for human abuse liability studies [10] . Female subjects of child-bearing potential were required to be using an effective form of birth control. All subjects were required to test negative for alcohol and drugs of abuse prior to dosing in the pharmacologic qualification and treatment phases.
The main exclusion criteria included any history of drug or alcohol dependence (as per Diagnostic and Statistical Manual of Mental Disorders criteria and including subjects who had ever entered a drug rehabilitation program), psychiatric or neurological illness, hyponatremia (serum sodium level ≤ 130 mmol/L), or any condition that may interfere with drug absorption, distribution, metabolism, or excretion. Subjects were restricted from using other prescription, nonprescription, or recreational drugs during the study.
Study design
The study consisted of four phases: screening, pharmacologic qualification, treatment, and follow-up. Randomization was performed using a computer-generated randomization schedule, and subjects and clinical research unit staff members were blinded to treatment assignment by use of identical drug capsules and/or tablets.
Within 28 days of screening, subjects attended a double-blind crossover pharmacologic qualification session to ensure that they could discriminate effects of the active control (ALP) compared with those of PBO. In order to be eligible to enter the treatment phase, subjects were required to meet the following qualification criteria: peak score in response to ALP N PBO on Drug-Liking VAS (difference of ≥10 points); acceptable PBO and ALP responses; available safety data at ALP 2.0 mg consistent with the subject being able to tolerate the ALP 3.0 mg dose as judged by the investigator or designee; and general behavior suggestive that the subject would be able to successfully complete the study, as judged by the clinic staff.
Thus, subjects were randomized to receive either a single dose of ALP (2.0 mg) or matching PBO in a double-blind crossover fashion, separated by a washout period of 24 h. Subjects qualified to enter the treatment phase if they met all qualification criteria.
The treatment phase consisted of seven 3-day visits, each separated by a washout interval of at least 7 days. Qualifying subjects were randomly assigned to a predetermined treatment sequence according to a two 7 × 7 Williams square design (14 sequences in total) and received a single dose of each of the following in a double-blind, doubledummy, crossover manner: ESL 800 mg, ESL 1600 mg, ESL 2000 mg, ESL 2400 mg, ALP 1.5 mg, ALP 3.0 mg, and PBO. The study was completed when subjects returned for a safety follow-up visit, which was scheduled 5-10 days after the last administration of study drug.
Pharmacodynamic assessments
Pharmacodynamic (PD) measures were collected over 24 h postdosing using validated computerized software (Scheduled Measurement System, SMS-INC Research, Toronto). Subjects rated perceptions of their subjective state and of the effects of the study drugs, using "at this moment" and "next-day" VASs, administered as unipolar and bipolar 100-point scales, as described by Schoedel et al. [16] ( Table 1 lists the test questions and response anchors for each VAS) and the 49-item Addiction Research Center Inventory (ARCI; each item answered as True or False, see Martin et al. [17] ). The Subjective Drug Value measure and measures for objective assessment of cognitive and psychomotor function were also administered. Subjects undertook training and practice sessions on relevant subjective outcome measures at the start of the pharmacologic qualification stage and prior to each treatment session. The primary outcome measure was the bipolar Drug-Liking VAS. Secondary outcome measures (subjective) included the unipolar VASs: Take Drug Again, High, Good Effects, Bad Effects, Any Effects, Dizziness, and Drug Similarity; the bipolar VASs: Overall Drug-Liking and Alertness/Drowsiness; the ARCI subscales: MorphineBenzedrine Group (MBG; euphoria), Pentobarbital Chlorpromazine Alcohol Group (PCAG; sedation), and Lysergic Acid Diethylamide Group (LSDG; dysphoria) scales [17] ; the Subjective Drug Value (method adapted from Griffiths et al. [18] ); and cognitive and psychomotor function measures: Choice Reaction Time (CRT; as per Milovan et al. [19] ), Divided Attention (DAT) [11, 19] , and Hopkins Verbal Learning Task-Revised (HVLT-R) tests [20, 21] .
Subjective measures were assessed predose (for measures not specifically referring to drug) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 h postdose. Overall Drug-Liking VAS, Take Drug Again VAS, and Subjective Drug Value were assessed at 10 and 24 h postdose, and Drug Similarity VAS was assessed at 10 h postdose. Choice Reaction Time and DAT were evaluated predose and at 1, 2, 4, 6, and 10 h postdose, and HVLT-R was performed predose and 0.5, 3, and 6 h postdose.
Pharmacokinetic assessments
Pharmacokinetic (PK) samples were collected within approximately 5 min of completing the PD assessments. Descriptive statistics were calculated per time point for plasma concentrations of ESL, eslicarbazepine, and (R)-licarbazepine. Concentration-time profiles for eslicarbazepine were analyzed via noncompartmental methods to estimate PK parameters in plasma, according to the model-independent approach. Plasma eslicarbazepine PK endpoints were the following: maximum observed plasma concentration (C max ), time to C max (t max ), area under the curve (AUC) from time zero to the last measurable concentration (AUC 0-last ), AUC from time zero to infinity (AUC 0-∞ ), drug half-life (t ½ ), elimination rate constant (λ z ), apparent total clearance (CL/F), and apparent volume of distribution (V z /F).
Safety and tolerability
Safety assessments included the following: the incidence, frequency, and severity of AEs (both spontaneously reported and as determined by the use of nonleading questions at specific time points); laboratory parameters (clinical chemistry, hematology, and urinalysis); and vital signs, physical examinations, and 12-lead electrocardiograms. Additionally, suicidal behavior was assessed using the Columbia-suicide severity rating scale (C-SSRS).
Data analyses
As determined by a paired t-test with a 2-sided significance level of 0.05, a sample size of 35 subjects was estimated to have ≥90% power to detect an 8.4-point difference in Drug-Liking VAS peak score (maximum effect [E max ]) using an estimated standard deviation (SD) of 14.8 (the pooled intrasubject SD from PBO, ALP 1.5 mg, and ALP 3 mg data [22] ). Based on an estimated 30% dropout rate, a sample size of 49 subjects was required for randomization to the treatment phase to ensure data from at least 35 subjects completing all treatments.
Randomized subjects who completed all treatment sessions and had no major protocol deviations were included in PD analyses. Pharmacokinetic analyses were conducted for the PK population (all randomized subjects who received at least one dose of ESL and for whom at least one PK sample was obtained after dosing and who had no protocol deviations that would exclude them from analysis). All subjects who received at least one dose of study drug during the treatment phase were included in the safety evaluation.
All statistical analyses were performed using SAS (version 9.2, SAS Institute Inc., Cary, NC, USA). Primary and secondary measures were summarized at each time point using descriptive statistics, and point estimates, 95% confidence intervals (95% CI) and p-values were generated for treatment comparisons. The major study endpoint was E max on the Drug-Liking VAS, for ESL versus PBO (primary) and ESL versus ALP (major secondary). For each measure, peak scores (E max and/or E min [minimum effect], as applicable) were analyzed using a linear mixedeffect analysis of covariance (ANCOVA) which included period, sequence, and treatment as fixed effects and subject within sequence as a random effect; predose observation was used as a covariate when available.
For all endpoints, the assumption on normal distribution of the data required for ANCOVA model was examined using normality test. If noticeable departures from normality assumptions were detected for any PD endpoint, nonparametric methods were used. The Friedman's method was used to test the overall treatment effect, whereas the Wilcoxon Signed Rank test was used to compare the pairwise treatment differences.
Results

Subject disposition and baseline characteristics
One hundred and eleven subjects were screened, 83 participated in the qualification session, and 56 met the qualification criteria. Of these, 53 were randomized to the treatment phase, and a total of 44 (83.0%) subjects completed all seven treatment periods of the study and were included in the PD analyses (see Fig. S1 for details of subject disposition). A total of nine subjects discontinued the study after receiving study medication: four due to AEs, two for administrative reasons, one due to physician decision, one due to noncompliance with the study, and one subject withdrew consent.
Of the 53 subjects randomized to the treatment phase, 43 (81.1%) were male, 49 (92.5%) were white, two were Black or AfricanAmerican (3.8%), one was Asian (1.9%), and one was of other race (1.9%). The mean (SD; range) age of subjects was 37 (9.4; 21-55) years, and the mean BMI was 25.4 (2.7; 18.1-30.2) kg/m 2 . In terms of previous recreational drug use, all 53 subjects had previously used CNS depressants, and 42 (79.2%), 35 (66.0%), 30 (56.6%), and 9 (17.0%) subjects had previously used cannabinoids, opioids, stimulants, and hallucinogens, respectively. Fig. 1A . The dose-response relationship seen with ALP use was relatively flat, whereas ESL was associated with a slightly increasing response with increasing dose (Fig. 1B) [21.5, 32 .1] for ALP 1.5 mg and 3.0 mg, respectively; p b 0.0001 for both), confirming study validity. DrugLiking VAS E max values for all ESL doses were significantly lower compared with those for 1.5 mg and 3.0 mg ALP (for all ESL doses, LS mean differences ranged from − 13.1 to − 23.2; all p b 0.0001; Table 2 ). Drug-Liking VAS E max values for the three highest ESL doses were statistically different from PBO: for ESL 1600 mg, ESL 2000 mg, and ESL 2400 mg, LS mean differences in E max were 9.3 (p = 0.0007), 12.2 (p b 0.0001), and 13.3 (p b 0.0001), respectively; whereas, the lowest dose of ESL 800 mg was not significantly different from PBO: LS mean difference in E max was 3.6 (p = 0.1885) (Fig. 2 and Table 2 ).
Overall Drug-Liking VAS, Take Drug Again VAS and Subjective Drug Value
For end-of-day/next-day measures, some values were significantly higher for ESL than for PBO; primarily at higher ESL doses (2000 mg and/or 2400 mg) but only for some endpoints ( Fig. 2 and Table 3 ). Scores for all endpoints for the measures were significantly higher for both doses of ALP than for PBO ( Fig. 2 and Table 3 ). Most endpoints for the measures were significantly lower with ESL (all doses) than with 1.5 mg and 3.0 mg ALP (Table 3 ).
Measures of positive effects 3.3.1. Good Effects VAS, ARCI MBG, and High VAS
Mean time-response profiles (ESL, ALP, and PBO) on the Good Effects VAS are presented in Fig. 3A . Good Effects VAS and High VAS scores were significantly higher for ESL (all doses) than for PBO, particularly at the higher doses. For the ARCI MBG ('euphoria') scale, only the 2400 mg ESL dose was significantly higher than PBO (Fig. 2 and Table 3 ). All endpoint measures were significantly higher than PBO with both ALP doses, while ESL (all doses) had significantly smaller effects than ALP (both doses) ( Table 3) .
Measures of negative effects
Bad Effects VAS, ARCI LSDG
Mean time-response profiles for the Bad Effects VAS are presented in Fig. 3B . Treatment effects on negative effect measures (Bad Effects VAS and ARCI LSDG) were modest for all doses of ESL compared with those of PBO. While statistically significant differences from PBO in E max were observed for Bad Effects VAS and ARCI LSDG with ESL 2000 mg and 2400 mg (and also with ESL 1600 mg for ARCI LSDG), the magnitude of these differences was relatively small compared with the differences observed between ALP and PBO (for Bad Effects VAS, median differences versus PBO were 0.5 for ESL 2000 mg and 0 for ESL 2400 mg, compared with 31 for ALP 1.5 mg and 40 for ALP 3.0 mg; Table 3 ). Therefore, the clinical relevance of the observed differences between ESL and PBO is unknown. Negative effects were generally greater with ALP (particularly at 3.0 mg) compared with those of ESL (Table 3) . In general, ESL showed greater sedative effects compared with PBO on the ARCI-PCAG and Alertness/Drowsiness VAS but smaller effects compared with ALP ( Fig. 2 and Table 3 ). Mean time-response profiles for the Any Effects VAS are presented in Fig. 4A . Any Effects VAS E max values for both ALP and ESL were significantly greater than for PBO ( Fig 4B and Table 3 ). Comparisons between ESL and ALP showed significantly greater mean E max scores for ALP versus ESL, except ESL 2400 mg versus ALP 1.5 mg (Fig. 2 and Table 3 ). Alprazolam and the three higher ESL doses were associated with greater Dizziness VAS scores than PBO, but ESL was associated with lower Dizziness VAS scores than ALP (Table 3) . On most secondary measures (e.g., Any Effects VAS; Fig. 4B ), the dose-effect relationship was relatively flat or showed saturation at the higher doses.
On Drug Similarity VAS, while ALP was identified strongly as a depressant (and to a lesser extent as an opioid), scores for ESL were more modest (Fig. S2) . Mean VAS scores indicating similarity with benzodiazepines, and to a lesser extent codeine/morphine, were higher for ALP than for PBO (benzodiazepines: ALP 1. The same was true (to a much lesser extent) for similarity with codeine/ morphine (ESL 800-2400 mg = 24.4-33.2; PBO = 9.0); scores for ESL were nevertheless lower than those for ALP. were seen with ALP, starting at 1 h postdose and lasting for at least 6 h postdose. Eslicarbazepine acetate showed less of an effect on these variables. A similar pattern of effects was observed on percentage correct responses (CRT) and number of false alarms and percentage target hits (DAT): decrements in performance were seen with ALP, but there was little or no effect of ESL (data not shown). Only ALP 3 mg showed an apparent effect on HVLT-R variables (delayed recall hits, percent retention, recognition discrimination index, and total number of errors), especially at 3 h postdose, while the effects of the other active treatments were minimal compared with those of PBO (data not shown).
Pharmacokinetics
Mean C max , AUC 0-last , and AUC 0-∞ increased with increasing ESL dose; the increases in AUC 0-last and AUC 0-∞ appeared to be dose proportional. The time to reach C max increased with increasing ESL dose, and the median t max occurred within approximately 1.6 to 3.1 h postdose, although it was delayed in some subjects up to 10 h postdose. Median t ½ ranged from 13 to 17 h, and mean CL/F and V z /F for eslicarbazepine were consistent across all dose groups.
Safety
Overall, ESL was relatively well tolerated in healthy recreational CNS depressant users. No deaths or serious AEs (SAEs) occurred during the study. Four subjects (7.5%) discontinued because of treatmentemergent AEs (TEAEs), which included an electrocardiogram T-wave inversion (n = 1, ESL 1600 mg), an increase in aspartate aminotransferase (AST; n = 1, PBO; n = 1, ESL 1600 mg), and toothache (n = 1, PBO). During the treatment phase, 22/49 (44.9%; PBO), 48/49 (98.0%; ALP 1.5 mg and 3.0 mg), 27/48 (56.3%; ESL 800 mg), 29/48 (60.4%; ESL 1600 mg), and 37/47 (78.7%; ESL 2000 mg and 2400 mg) had at least one TEAE (Table 4) . Most TEAEs were mild or moderate, and the majority of events were considered at least possibly related to study drugs. Somnolence (33.3-51.1%), oral paresthesia (12.5-27.7%), fatigue (4.2-17.0%), and headache (6.3-12.8%) were the most common TEAEs associated with ESL doses. Somnolence was the most common TEAE associated with ALP doses (83.7-89.8%); euphoric mood (14.3-20.4%), fatigue (16.3-24.5%), and dizziness (6.1-10.2%) were also relatively common. The most common TEAEs with PBO were somnolence (20.4%), headache (12.2%), and fatigue (6.1%). The majority of potentially abuse-related events were sedative-type events (primarily somnolence), and the incidence of these events (in particular, somnolence) was higher with ALP doses than with ESL.
Clinical laboratory values were within normal ranges at all assessments. However, a number of related TEAEs and abnormalities were reported. In six subjects, hemoglobin levels were normal at baseline and abnormally low at follow-up. Other parameters that were normal at baseline and abnormal at follow-up were the following: plasma albumin (seven subjects), sodium (six), lactate dehydrogenase (four), Fig. 3 . 'Good Effects' and 'Bad Effects' VAS scores: time-response profiles for ESL, ALP, and PBO. A) 'Good Effects' VAS scores ("I can feel good drug effects"). B) 'Bad Effects' VAS scores ("I can feel bad drug effects"). Data are mean scores ± SE over time, up to 24 h postdose. 0 = 'definitely not'; 100 = 'definitely so'. ALP, alprazolam; ESL, eslicarbazepine acetate; PBO, placebo; SE, standard error; VAS, visual analog scale. Fig. 4 . 'Any Effects' VAS scores: time-response profiles and dose-response relationships for ESL, ALP, and PBO. A) 'Any Effects' VAS scores (mean ± SE). ("I can feel any drug effects"); 0 = 'definitely not'; 100 = 'definitely so'. B) Dose-response relationship for 'Any Effects' VAS E max (mean ± 95% CI). ALP, alprazolam; CI, confidence interval; E max , maximum effect; ESL, eslicarbazepine acetate; PBO, placebo; SE, standard error; VAS, visual analog scale.
AST (three), and urea concentrations (three). AEs related to these parameters were reported in three subjects. A slight increase in heart rate and a decrease in blood pressure occurred with ALP, otherwise mean vital sign values were within normal range (one subject had a TEAE of increased blood pressure). Mean values for all electrocardiogram (ECG) parameters were within normal range, although one subject experienced an ECG-related TEAE. There were no clinically significant findings relating to physical examination or C-SSRS during the study.
Discussion and conclusions
The study was designed and performed according to guidelines for the assessment of abuse liability in humans [10, [13] [14] [15] . In particular, this study enrolled and randomized recreational drug users with a history of CNS depressant use who were able to discern between PBO and the active control, ALP. As expected, ALP was associated with significant abuse-related effects compared with PBO, including primary outcome measures such as Drug-Liking VAS. Consistent with these findings, ALP was strongly identified as a benzodiazepine on the Drug Similarity VAS and was not identified as PBO. Together, these findings confirm the validity and sensitivity of the study. Notably, when compared with PBO, both doses of ALP were also associated with some negative effects as measured on the Bad Effects VAS and ARCI LSDG scale. The balance of effect measures (e.g., Overall Drug-Liking VAS) demonstrated that, overall, both ALP doses were 'liked'. However, the negative effects seen with the higher dose of ALP may have contributed to the relatively flat dose-response observed for some measures with ALP.
Based on the overall pattern of responses, in comparison with PBO and ALP, this study demonstrated that ESL 800 mg was not significantly different from PBO with respect to measures of abuse liability. Therefore, patients taking this dose of ESL and recreational drug users experimenting with single 800-mg tablets would not be expected to experience abuse-related subjective effects. Additionally, the observed ESL dose-response relationships were relatively shallow or showed saturation at higher doses for most secondary measures, suggesting that an appropriate range of doses was evaluated and that further dose escalation of ESL would not result in substantially greater subjective effects. The highest dose of ESL approved by the FDA (1600 mg) [23] and the supratherapeutic doses of ESL (2000 mg and 2400 mg) had detectable subjective effects compared with those of PBO, as demonstrated by statistical differences on most PD endpoints, including the primary study endpoint (Drug-Liking VAS E max ). However, the magnitude of these differences was generally small (e.g., LS mean difference in Drug-Liking VAS E max of 9.3 for ESL 1600 mg versus PBO [p = 0.0007]).
Abuse liability studies of AEDs recently approved by the FDA have shown no statistically significant differences between benzodiazepinepositive controls and pregabalin [24] or retigabine [25] . Lacosamide produced euphoria-type subjective responses that differentiated statistically from placebo at 800 mg; these euphoria-type responses were statistically indistinguishable from those produced by ALP [26, 27] . By comparison, in the present study, ESL (all four doses) had significantly smaller effects than ALP (both doses) on the primary endpoint and the vast majority of secondary subjective and objective endpoints. Our interpretation of these small effects is that they are unlikely to be clinically significant. In terms of the Drug Similarity VAS, subjects rated ESL as being somewhat similar to benzodiazepines, although this may have been partly attributable to the occurrence of sedative-type effects, which are known potential side effects associated with ESL [3, 5] and are common within the AED class.
Furthermore, preclinical studies have demonstrated a lack of clinically relevant interactions between eslicarbazepine and gammaaminobutyric acid-type A (GABA A ) receptors (data on file, Sunovion Pharmaceuticals Inc.). In contrast, carbamazepine potentiates chloride currents in cells expressing human GABA A receptors at clinically relevant concentrations [28] . Positive allosteric modulation of GABAA receptors associated with drugs such as benzodiazepines and nonbenzodiazepine sedative hypnotics leads to sedating, anxiolytic, and hypnotic effects, all of which may be reinforced with long-term exposure to these drugs and may therefore contribute to abuse liability [29] . The absence of GABA A -modulating properties for eslicarbazepine would therefore be expected to yield lower liabilities related to abuse liability, particularly in comparison with drugs with known abuse liability such as the benzodiazepines.
Eslicarbazepine acetate demonstrated impairment on some but not all of the cognitive and psychomotor performance measures. Some significant differences were observed on the CRT total reaction time, and scores on the DAT test indicated significant differences in mean hit latency (i.e., slower reaction time) and percentage over the road (i.e., manual tracking) with the higher doses of ESL versus PBO. Other objective measures, such as HVLT-R, showed no significant impairments of verbal learning or memory by any dose of ESL. In contrast, ALP demonstrated significant dose-dependent impairment for the majority of cognitive endpoints, and these effects were significantly greater than those of ESL. The present findings in recreational CNS depressant users are broadly consistent with the results of an earlier study that examined the effect of ESL on cognition and psychomotor function in healthy volunteers [19] . For example, at a dose of ESL 800 mg, CRT LS mean total reaction time was 936 ms (95% CI: 934-1062), and DAT LS mean percentage over the road was 69% (95% CI: 59-75 [19] ).
Single doses of ESL up to 2400 mg were relatively well tolerated in healthy recreational CNS depressant users; no deaths or SAEs were reported during this study, and ESL showed a lower incidence of AEs compared with ALP, in particular, for the common events of somnolence and euphoric mood. A higher incidence of paresthesia and lower incidences of nausea and vomiting with ESL were noted in the present study (in recreational drug users) compared with those in previous studies of ESL in healthy volunteers. Abuserelated AEs were generally consistent with PD measures. Although some subjects had AEs related to vital signs, ECG, and laboratory tests, there were no apparent treatment-related effects on these parameters.
Study limitations include the single-dose design of the study and the use of subjective measures of drug effects alone rather than in combination with direct assessments of abuse such as self-administration models. However, the study design and endpoints are consistent with relevant guidelines for human abuse liability studies [10] . Furthermore, subjective measures often demonstrate concordance with other methods of abuse liability assessment [30] , and subjects were blinded to treatment assignment, thus lowering the risk of detection bias.
In conclusion, this study demonstrated that single doses up to 2400 mg of ESL had less impact on measures of abuse liability than did ALP in recreational CNS depressant users. Although ESL had detectable subjective effects and showed some drug-'liking' at higher doses, the magnitude of these effects was small. involved in the design and conduct of the study and the collection, management, and analysis of the data. Medical writing support was funded by Sunovion Pharmaceuticals Inc. and was provided by Jenny Wilkinson, Ph.D. of FireKite, an Ashfield company, part of UDG Healthcare plc.
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